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Copyright © 2009 JCBN Summary Fatty liver is commonly associated with alcohol or metabolic syndrome. We aimed
to examine the longitudinal aspects of fatty liver, and clarify the independent predictors for
the development or regression of fatty liver. In the present study, the clinical features of 1578
Japanese adults (1208 men and 370 women; 35 to 69 years of age) who visited our center both
in 2000 and 2007–2008 were recorded and compared, including liver status diagnosed by
ultrasonography. Of the 1578 participants, 217 (13.8%) showed fatty liver development, and
74 (4.7%) showed fatty liver regression. Logistic regression analysis revealed that body mass
index and percentage body fat were strongly associated with the development or regression of
fatty liver. Metabolic syndrome-related disorders such as serum levels of total cholesterol,
triglyceride, uric acid, and fasting blood glucose were also associated with clinical course to
some degree. However, the history of alcohol intake, the presence of metabolic syndrome,
blood pressure, and habitual physical exercise were not independent predictors for the
development or regression of fatty liver. Our present data suggest that control of body weight
in men and the percentage body fat in women are particularly important for the prevention
or treatment of fatty liver.
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Introduction
Fatty liver (steatosis) is defined as an accumulation of fat,
mainly triglyceride, in liver cells. This disease is commonly
associated with alcohol or metabolic syndrome (diabetes
mellitus, hypertension, and dyslipidemia) [1]. In particular,
non-alcoholic fatty liver diseases (NAFLD) are recognized
as the hepatic manifestation of metabolic syndrome and the
prevalence of this entity is increasing in many countries
[2–4]. In Japan, Kojima et al. [ 5] reported that the pre-
valence of fatty liver rose gradually from 12.6% in 1989
to 30.3% in 1998; this was mainly due to an increase in
body mass index (BMI). Hamaguchi et al. [6] reported thatPredictive Factors for Fatty Liver
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metabolic syndrome was a risk factor for the development of
NAFLD, and conversely, Fan et al. [4] suggested that the
presence of NAFLD might predict the development of
metabolic syndrome. Lifestyle changes, including weight
loss and physical exercise, have been shown to improve the
clinical course in NAFLD [3, 7].
In our previous study, we examined the frequency of fatty
liver diagnosed by ultrasonography (USG) in 3432 Japanese
adults who visited Health Service Center, Mitsubishi Heavy
Industries, Ltd., Nagasaki Shipyard and Machinery Works
Hospital, Nagasaki, Japan for a thorough medical examina-
tion between January and December 2000 and found that
BMI was the most independent predictor for the presence
of fatty liver in both sexes [8]. We further reported that
percentage body fat was a useful index to assess the etiology
of fatty liver in non-alcoholic and non-overweight partici-
pants, particularly women.
In the present study, we aimed to examine the longitudinal
aspects of fatty liver in each participant who visited the
same health checkup center. We also clarified the independent
predictors for the development or regression of fatty liver in
non-alcoholic participants.
Materials and Methods
Study participants
Of the 3432 Japanese participants who visited the Health
Service Center, Mitsubishi Heavy Industries, Ltd., Nagasaki
Shipyard and Machinery Works Hospital, Nagasaki, Japan
for a thorough medical examination between January and
December 2000 (in 2000) [8], 1589 also visited the same
Center between April 2007 and March 2008 (in 2007–2008).
The medical examination was performed for subjects who
visited the hospital voluntarily (most of them were employees
or their families) to promote public health through early
detection of chronic diseases. Of these 1589 participants, we
excluded 6 participants who turned positive for anti-hepatitis
C virus antibody and 5 participants who did not undergo
USG in 2007–2008 from the present study. Therefore, the
total number of study subjects was 1578 (1208 men and 370
women; mean age, 54.0 ± 4.7 years; range, 35 to 69 years).
This study was performed according to the principles of the
Declaration of Helsinki. The study protocol was approved
by the Ethical Committees of Siebold University of
Nagasaki and Mitsubishi Heavy Industries, Ltd., Nagasaki
Shipyard and Machinery Works Hospital. Informed consent
was obtained from all participants.
Data collection and measurements
The medical examination was performed between 8:00–
11:00 am after overnight fasting. The information obtained
from the medical records for the present study included sex,
age, height, body weight, history of alcohol intake, present
physical exercise habit, history of medical treatment for
hypertension, dyslipidemia, and/or diabetes mellitus, systolic
blood pressure (SBP), diastolic blood pressure (DBP),
serum levels of aspartate aminotransferase (AST), alanine
aminotransferase (ALT), γ-glutamyl transpeptidase (GGTP),
total choresterol (T.Chol.), triglyceride (TG), uric acid (UA),
fasting blood glucose (FBG), percentage body fat (% fat
volume), and liver status by USG.
The history of alcohol intake, present physical exercise
habit and history of medical treatment for hypertension,
dyslipidemia and/or diabetes mellitus were determined by
questionnaire. The history of alcohol intake was divided
into three groups as follows: never drinker, heavy drinker
(at least 70 g/day of alcohol intake more than 5 times per
week), and moderate drinker (neither never drinker nor
heavy drinker). Regarding the present physical exercise
habit, participants marked “yes” if they had a habit of
physical exercise such as jogging, walking, or playing
tennis, golf, or badminton. Regarding the history of medical
treatment for hypertension, dyslipidemia and/or diabetes
mellitus, participants marked “yes” if they had been receiving
medical treatment for such diseases.
The body mass index (BMI) was calculated as body
weight (kg) divided by height (m2). Overweight was defined
as a BMI of ≥25 kg/m2 [9]. The percentage body fat mea-
surement was performed using a bipedal bioimpedance
instrument (Body Fat Analyzer TBF-202; Tanita, Tokyo,
Japan). Obesity was defined for Japanese adults as ≥25%
body fat for men and ≥30% body fat for women [8].
Abdominal ultrasonography was performed by clinical
hepatogastroenterologists or trained technicians without
knowledge of the anthropometric and laboratory data. When
USG was performed by a trained technician, one hepato-
gastroenterologist reviewed the stored ultrasonographic
images and made the final diagnosis. The diagnosis of fatty
liver by USG (Aloka Pro Sound SSD-4000; Aloka, Tokyo,
Japan) was based on the findings of “bright liver” (increased
echogenicity) with “liver-kidney contrast” (increased echo
level of the liver compared with the right kidney). “Vascular
blurring” (blurring of the hepatic vein) and “deep attenua-
tion” (attenuation of the echo level in the deep region of the
liver) were also seen in many cases, but their absence did
not exclude the diagnosis of fatty liver.
The standard Japanese criteria for the diagnosis of
metabolic syndrome are as follows. The presence of visceral
fat accumulation (defined as waist circumference ≥85 cm
for men and ≥90 cm for women) is an indispensable factor,
with any two or more of the following criteria: (1) a high
serum level of triglyceride (≥150 mg/dL or ≥1.7 mmol/L)
and/or low serum level of high-density lipoprotein (HDL)
cholesterol (<40 mg/dL or <1.03 mmol/L) or receiving
specific treatment for these abnormalities; (2) high blood
pressure (SBP ≥130 mmHg and/or DBP ≥85 mmHg) orK. Omagari et al.
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receiving specific treatment for hypertension; (3) high FBG
concentration (≥110 mg/dL or ≥6.11 mmol/L) or receiving
specific treatment for glucose abnormality [10]. Because
waist circumference and serum level of HDL cholesterol
were not available in our study subjects, we substituted a
BMI ≥25 kg/m2 for waist circumference, and omitted the
HDL cholesterol. Therefore, we defined a “tentative
metabolic syndrome” as follows: BMI ≥25 kg/m2 plus at
least two of the following three factors: (1) a high serum
level of triglyceride (≥150 mg/dL) or receiving specific
treatment for triglyceride abnormality; (2) high blood
pressure (SBP ≥130 mmHg and/or DBP ≥85 mmHg) or
receiving specific treatment for hypertension; (3) high FBG
concentration (≥110 mg/dL) or receiving specific treatment
for glucose abnormality. Serum level of low-density lipo-
protein (LDL) cholesterol was also unavailable in our study
population.
Comparison of data between 2000 and 2007–2008
In the comparison of each individual participant’s data
between 2000 and 2007–2008, “% change” in BMI and the
percentage body fat was calculated as follows: {[(data in
2007–2008) − (data in 2000)] / data in 2000} × 100.
“Change” in blood pressures and laboratory data was
calculated as follows: (data in 2007–2008) − (data in 2000).
Regarding alcohol behavior, participants were divided into
following four groups: non-drinker {never drinker or occa-
sional drinker (1–4 times per week) in 2000 [8], and never
drinker in 2007–2008}; continuous drinker {almost every
day drinker (at least 23 g/day of alcohol intake 5–7 times per
week) in 2000 [8], and heavy drinker or moderate drinker in
2007–2008}, former drinker (almost every day drinker in
2000 and never drinker in 2007–2008); and others (neither
non-drinker, continuous drinker, nor former drinker).
Statistical analysis
Data were expressed as mean ± standard deviation (SD)
or median (range). Differences between groups were
examined for statistical significance using the two-tailed
Mann-Whitney U test, Wilcoxon signed-rank test, chi-square
test, or Fisher’s exact probability test. Multivariate analysis
for the development or regression of fatty liver was per-
formed for variables that were significant in univariate
analyses using logistic regression analysis. Correlations
were examined by linear regression analysis using the
coefficient of correlation. All data analyses were performed
using SPSS statistical package, version 16.0J (SPSS, Inc.,
Chicago, IL) on a computer with a Windows operating
system. A p-value less than 0.05 was considered statistically
significant.
Results
Clinical and laboratory features of participants in 2007–
2008
The participants’ age in 2007–2008 was significantly
higher in men (54.4 ± 4.7 years; range, 41 to 69 years)
than in women (52.7 ± 4.6 years; range, 35 to 65 years)
(p<0.001). The number and frequency of participants for
each clinical and laboratory feature are shown in Table 1.
Of the 1578 participants, fatty liver was diagnosed by USG
in 501 (31.7%). Of the 370 women in the study, 247 (66.8%)
were obese (≥30% fat volume).
Fatty liver was more frequently seen in men and over-
weight as well as obese participants. Systolic and diastolic
blood pressure, serum levels of AST, ALT, GGTP, T.Chol,
TG, UA, and FBG were higher in participants with fatty
liver than in those with non-fatty liver. Participants who
have “tentative metabolic syndrome” and who had been
receiving treatment for hypertension, dyslipidemia and/or
diabetes mellitus were more frequently found in the fatty
liver group. In contrast, there were no significant differences
in age and the proportion of alcohol drinker between the
fatty liver and non-fatty liver groups of participants. Physical
exercise habit was more common in the non-fatty liver
group (Table 2).
Comparison of clinical and laboratory features between
2000 and 2007–2008
The median interval in thorough medical examinations
between 2000 and 2007–2008 was 84.0 months (range, 76 to
98 months). Between 2000 and 2007–2008, the change in
median body weight, BMI, and percentage body fat was
+0.8 kg (range, −16.4 to +19.8 kg), +0.4 kg/m2 (range, −5.4
to +7.6 kg/m2), and +0.2% (range, −11.2 to +21.7%), respec-
tively. Body mass index, percentage body fat, serum levels
of AST, ALT, GGTP, T.Chol., TG, UA, and FBG were higher
in participants in 2007–2008 than in 2000. In contrast,
DBP was lower in 2007–2008 than in 2000 (Table 3). In
2000, fatty liver was diagnosed by USG in 358 of the 1578
participants. Of these 358 participants, 284 had fatty liver in
2007–2008. Of the 1220 participants who did not have fatty
liver in 2000, 217 had fatty liver in 2007–2008 (Fig. 1).
Clinical and laboratory features of participants who were
classified as non-drinkers
To determine the clinical and laboratory features of fatty
liver and non-fatty liver in non-alcoholic participants, the
data from 346 participants who were classified as non-
drinkers [never drinker or occasional drinker (1–4 times per
week) in 2000 [8] and never drinker in 2007–2008] were
analyzed. Of these 346 participants, 102 had fatty liver in
2007–2008 and fatty liver was more frequently seen in men,
overweight, and obese participants. Systolic and diastolicPredictive Factors for Fatty Liver
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blood pressures, serum levels of AST, ALT, GGTP, TG, UA,
and FBG were higher in participants with fatty liver than in
those without fatty liver. Participants who had “tentative
metabolic syndrome” and who had been receiving treatment
for hypertension, dyslipidemia and/or diabetes mellitus were
more frequently found in the fatty liver group. In contrast,
there were no significant differences in age and serum level
of T.Chol. between participants with and without fatty liver.
Physical exercise habit was more common in the non-fatty
liver group (Table 4). In 2000, fatty liver was diagnosed in
73 of the 346 participants who were classified as non-
drinkers. Of these 73 participants, 12 no longer had evidence
of fatty liver in 2007–2008. Of the 273 participants who
were classified as non-drinkers and who did not have fatty
liver in 2000, 41 had fatty liver in 2007–2008 (Fig. 2).
Comparison of clinical and laboratory features of fatty liver
and non-fatty liver in 2007–2008
Men and women were separately analyzed in comparisons
of clinical and laboratory features of fatty liver and non-fatty
liver in 2007–2008 in participants who did not have fatty
liver in 2000 (n = 1220). Body mass index in 2000, %
change in BMI, percentage body fat in 2000, % change in
percentage body fat, TG in 2000, change in UA, and change
in FBG were higher in participants who had fatty liver in
2007–2008 in both sexes. Also, the development of “tenta-
tive metabolic syndrome” was more common in participants
who had fatty liver in 2007–2008 in both sexes. Systolic
blood pressure and T.Chol. in 2000, and change in TG were
higher in men who had fatty liver in 2007–2008. Participants
who had been receiving specific treatment for hypertension,
dyslipidemia and/or diabetes mellitus were more frequent
Table 1. Number and frequency of participants for each clinical and laboratory feature in
2007–2008 (n = 1578)
USG, ultrasonography; ND, not described; BMI, body mass index; SBP, systolic blood
pressure; DBP, diastolic blood pressure; AST, aspartate aminotransferase; ALT, alanine
aminotransferase; GGTP, gamma-glutamyl transpeptidase; T.Chol., total cholesterol; TG,
triglyceride; UA, uric acid; FBG, fasting blood glucose; HT, hypertension; DL, dyslipidemia;
DM, diabetes mellitus.
Feature No. of subjects Frequency (%)
Fatty liver by USG 501 31.7
Alcohol consumption
Never drinker 365 23.1
Drinker 1098 69.6
Heavy drinker 71 4.5
ND 44 2.8
Physical exercise habit
Yes 536 34.0
No 1031 65.3
ND 11 0.7
BMI≥25 kg/m2 414 26.2
% fat volume excess (men and women) 596 37.8
% fat volume≥25% (men) 349 28.9
% fat volume≥30% (women) 247 66.8
SBP≥130 mmHg 505 32.0
DBP≥85 mmHg 194 12.3
AST≥34 IU/L 145 9.2
ALT≥43 IU/L 158 10.0
GGTP≥48 IU/L 558 35.4
T.Chol.≥220 mg/dL 637 40.4
TG≥150 mg/dL 393 24.9
UA≥7.6 mg/dL 167 10.6
FBG≥110 mg/dL 302 19.1
Tentative metabolic syndrome 164 10.4
Receiving treatment for HT, DL, and/or DM 430 27.2K. Omagari et al.
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in men who had fatty liver in 2007–2008 (Table 5). In
participants who had fatty liver in 2000 (n = 358), TG in
2000 and change in FBG were significantly lower in
participants whose fatty livers had regressed by 2007–2008
in both sexes. Body mass index in 2000, % change in BMI,
percentage body fat in 2000, % change in percentage body
fat, and UA in 2000 were lower in men whose fatty livers
had regressed by 2007–2008. Also, the development of
“tentative metabolic syndrome” was less common in men
whose fatty livers had regressed by 2007–2008. Non-
drinkers were less common in women whose fatty livers
had regressed by 2007–2008 (Table 6).
Table 2. Comparison of clinical and laboratory features of fatty liver and non-fatty liver in 2007–2008 (n = 1578)
Age, BMI, % fat volume, blood pressure and biochemical data are expressed as median (range).
NV, normal value. Refer to the legend of Table 1 for other abbreviations.
Feature
Fatty liver 
(n = 501)
Non-fatty liver 
(n = 1077)
p
Men/women 427/74 781/296 <0.001
Age (years) 55 (41–69) 55 (35–69) 0.514
Alcohol (heavy/moderate/never drinker) 22/356/107 49/742/258 0.642
Physical exercise habit (yes/no) 138/359 398/672 0.001
BMI (kg/m2) 25.1 (17.4–46.0) 22.3 (12.8–32.8) <0.001
% fat volume (men) 25.7 (14.0–42.0) 20.8 (7.0–35.0) <0.001
% fat volume (women) 34.3 (22.5–53.8) 26.2 (6.6–41.3) <0.001
SBP (mmHg) 126 (88–161) 121 (81–177) <0.001
DBP (mmHg) 76 (54–101) 74 (45–105) <0.001
AST (IU/L) (NV: 13–33) 25 (9–137) 21 (11–69) <0.001
ALT (IU/L) (NV: 8–42) 31 (2–169) 19 (5–123) <0.001
GGTP (IU/L) (NV: 10–47) 50 (12–850) 30 (5–701) <0.001
T.Chol. (mg/dL) (NV: 130–219) 216 (150–370) 211 (115–319) 0.003
TG (mg/dL) (NV: 46–149) 132 (42–1116) 92 (20–990) <0.001
UA (mg/dL) (NV: 2.6–7.5) 6.3 (0.7–12.0) 5.5 (1.8–11.8) <0.001
FBG (mg/dL) (NV: 70–109) 103 (76–295) 97 (66–221) <0.001
Tentative metabolic syndrome (present/absent) 131/370 33/1044 <0.001
Receiving treatment for HT, DL, and/or DM (yes/no) 185/316 245/832 <0.001
Table 3. Comparison of clinical and laboratory features between 2000 and 2007–2008
(n = 1578)
Data are expressed as median (range).
Refer to the legend of Table 1 for abbreviations.
Feature 2000 2007–2008 p
BMI (kg/m2) 22.8 (14.8–45.1) 23.1 (12.8–46.0) <0.001
% fat volume (men) 22.2 (9.2–52.6) 22.4 (7.0–42.0) 0.008
% fat volume (women) 26.9 (11.5–49.8) 27.6 (6.6–53.8) 0.008
SBP (mmHg) 121 (79–199) 123 (81–177) 0.937
DBP (mmHg) 76 (43–121) 75 (45–105) <0.001
AST (IU/L) 20 (9–153) 22 (9–137) <0.001
ALT (IU/L) 19 (2–130) 21 (4–169) <0.001
GGTP (IU/L) 28 (6–438) 36 (5–850) <0.001
T.Chol. (mg/dL) 207 (106–334) 212 (115–370) <0.001
TG (mg/dL) 93 (22–1516) 104 (20–1116) <0.001
UA (mg/dL) 5.5 (1.0–10.0) 5.8 (0.7–12.0) <0.001
FBG (mg/dL) 94 (65–243) 99 (66–295) <0.001Predictive Factors for Fatty Liver
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In participants who were classified as non-drinkers and
who did not have fatty liver in 2000 (n = 273), body mass
index in 2000, % change in BMI, percentage body fat in
2000, and % change in percentage body fat were signifi-
cantly higher in participants who had fatty liver in 2007–
2008 in both sexes. Total cholesterol and TG in 2000 were
also higher in men who had fatty liver in 2007–2008. In
women, change in TG and UA were higher in participants
who had fatty liver in 2007–2008 (Table 7). In participants
who were classified as non-drinkers and who had fatty liver
in 2000 (n = 73), % change in BMI, % change in percentage
body fat, and change in FBG were significantly lower in
men whose fatty livers regressed in 2007–2008. Because
there were only two women whose fatty livers regressed
in 2007–2008, statistical analysis between features of fatty
and non-fatty liver participants in 2007–2008 could not
sufficiently performed in women (Table 8).
Table 4. Comparison of clinical and laboratory features of fatty liver and non-fatty liver in 2007–2008 in participants who
were classified as non-drinkers (n = 346)
Age, BMI, % fat volume, biochemical and blood pressure data are expressed as median (range).
NV, normal value. Refer to the legend of Table 1 for other abbreviations.
Feature
Fatty liver 
(n = 102)
Non-fatty liver 
(n = 244)
p
Men/women 59/43 96/148 0.002
Age (years) 55 (42–65) 54 (35–63) 0.359
Physical exercise habit (yes/no) 17/83 72/170 0.034
BMI (kg/m2) 25.2 (19.4–45.2) 21.6 (16.2–32.8) <0.001
% fat volume (men) 24.5 (19.0–34.6) 19.8 (10.6–30.7) <0.001
% fat volume (women) 34.5 (25.3–53.8) 26.5 (14.3–40.6) <0.001
SBP (mmHg) 123 (91–161) 118 (82–177) 0.002
DBP (mmHg) 73.5 (58–93) 70 (48–103) 0.001
AST (IU/L) (NV: 13–33) 23 (12–91) 20 (11–61) <0.001
ALT (IU/L) (NV: 8–42) 30 (11–112) 17 (5–69) <0.001
GGTP (IU/L) (NV: 10–47) 33 (12–140) 19 (9–534) <0.001
T.Chol. (mg/dL) (NV: 130–219) 216 (163–370) 213.5 (119–319) 0.360
TG (mg/dL) (NV: 46–149) 118 (49–349) 80 (30–484) <0.001
UA (mg/dL) (NV: 2.6–7.5) 5.5 (3.1–9.3) 4.8 (2.2–8.6) <0.001
FBG (mg/dL) (NV: 70–109) 102 (76–175) 94 (66–129) <0.001
Tentative metabolic syndrome (present/absent) 21/81 1/243 <0.001
Receiving treatment for HT, DL, and/or DM (yes/no) 32/70 42/202 0.003
Fig. 1. Number of participants with fatty liver and non-fatty
liver in 2000 and 2007–2008 (n = 1578)
Fig. 2. Number of participants who were classified as non-
drinkers with fatty liver and non-fatty liver in 2000 and
2007–2008 (n = 346)K. Omagari et al.
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Independent predictors for the development or regression of
fatty liver in 2007–2008 by logistic regression analysis
The logistic regression analysis showed that high
percentage body fat in 2000, increase in UA, and positive %
change in percentage body fat were independent predictors
for the development of fatty liver in 2007–2008 in both
sexes. In addition, positive % change in BMI, increase in
FBG, and high serum levels of T.Chol. and TG were
independent predictors for the development of fatty liver in
2007–2008 in men. Negative % change in BMI and low
BMI in 2000 were independent predictors for the regression
of fatty liver in 2007–2008 in men, and a decrease in FBG
was an independent predictor for the regression of fatty liver
in 2007–2008 in women (Table 9).
In participants who were classified as non-drinkers,
positive % change in BMI and high percentage body fat in
2000 were independent predictors for the development of
fatty liver in 2007–2008 in men and women, respectively.
Negative % change in BMI and decrease in FBG were
independent predictors for the regression of fatty liver in
2007–2008 in men (Table 9).
Discussion
The relation between fatty liver and metabolic syndrome-
related disorders such as obesity is well known, but data
from longitudinal observation (with sufficient duration) of
individuals in a large population are hitherto sparse. Kojima
et al. [5] reported that 5088 (14.3%) of 35519 participants
developed fatty liver, and that fatty liver resolved in 1248
(3.5%) of those participants during the follow-up period
from 1989 to 2000. They further reported that BMI, as well
as the relative change in BMI in each individual, was related
to the onset of fatty liver, followed by serum levels of TG
Table 5. Comparison of clinical and laboratory features of fatty liver and non-fatty liver in 2007–2008 in participants who did not have
fatty liver in 2000 (n = 1220)
* % change was calculated as follows: {[(data in 2007–2008) – (data in 2000)] / data in 2000} × 100.
** Change was calculated as follows: (data in 2007–2008) – (data in 2000).
Age, BMI, % fat volume, biochemical and blood pressure data are expressed as median (range).
Refer to the legend of Table 1 for abbreviations.
Feature
Men (n = 891) Women (n = 329)
Fatty liver 
in 2007–2008 
(n = 177)
Non-fatty liver 
in 2007–2008 
(n = 714)
p
Fatty liver 
in 2007–2008 
(n =4 0 )
Non-fatty liver 
in 2007–2008 
(n = 289)
p
Age (years) in 2000 48 (34–61) 48 (34–62) 0.121 47 (36–53) 46 (29–58) 0.367
Alcohol in 2000 (drinker/non-drinker) 119/58 508/206 0.307 4/36 30/259 0.941
Alcohol behavior 
(non-drinker/continuous/former drinker/others)
19/115/1/36 86/482/11/117 0.552 22/3/1/13 146/28/2/108 0.751
Physical exercise habit (yes/no) 59/116 278/430 0.375 11/29 102/186 0.572
BMI (kg/m2) in 2000 23.4 (18.5–32.8) 22.3 (16.5–28.3) <0.001 22.9 (18.4–28.8) 21.0 (14.8–28.6) <0.001
% change in BMI* +4.6 (−10.3–+18.9) +1.0 (−14.2–+22.6) <0.001 +6.8 (−9.2–+38.8) +0.5 (−17.7–+19.9) <0.001
% fat volume in 2000 22.6 (14.0–32.0) 20.7 (9.2–35.6) <0.001 30.5 (22.2–39.3) 25.7 (11.5–41.0) <0.001
% change in % fat volume* +7.7 (−38.1–+66.2) −0.5 (−47.1–+75.4) <0.001 +9.0 (−18.5–+84.2) +0.3 (−42.6–+106.0) <0.001
SBP (mmHg) in 2000 124 (88–199) 121 (83–165) 0.003 120 (85–176) 115 (79–163) 0.085
Change in SBP (mmHg)** +1 (−53–+43) +1 (−48–+49) 0.655 −1 (−42–+58) +2 (−38–+42) 0.440
DBP (mmHg) in 2000 77 (56–121) 77 (47–100) 0.061 74.5 (53–114) 71 (43–100) 0.213
Change in DBP (mmHg)** −1 (−32–+27) −2 (−40–+26) 0.436 −1.5 (−20–+16) −1 (−28–+25) 0.435
T.Chol. (mg/dL) in 2000 212 (142–298) 202 (123–334) 0.003 205 (159–314) 205 (106–321) 0.669
Change in T.Chol. (mg/dL)** +10 (−107–+87) +6 (−159–+91) 0.065 +26 (−103–+112) +19 (−109–+98) 0.202
TG (mg/dL) in 2000 119 (42–656) 88.5 (26–1516) <0.001 76 (40–166) 63 (22–236) 0.002
Change in TG (mg/dL)** +20 (−425–+323) +7 (−535–+831) <0.001 +20.5 (−58–+167) +14 (−73–+192) 0.065
UA (mg/dL) in 2000 5.7 (2.8–8.7) 5.7 (1.7–9.5) 0.146 4.2 (2.0–7.4) 4.1 (1.7–7.5) 0.713
Change in UA (mg/dL)** +0.6 (−3.7–+3.2) +0.3 (−3.4–+4.0) <0.001 +0.8 (−1.1–+2.1) +0.3 (−1.5–+2.3) <0.001
FBG (mg/dL) in 2000 94 (65–158) 94 (75–203) 0.550 90 (78–132) 90 (65–120) 0.788
Change in FBG (mg/dL)** +8 (−12–+80) +5 (−58–+82) <0.001 +7 (−13–+42) +2 (−19–+76) 0.014
Tentative metabolic syndrome in 2000 
(present/absent)
2/175 13/701 0.523 1/39 2/287 0.323
Change in tentative metabolic syndrome 
between 2000 and 2007–2008 
(present-present/present-absent/absent-present/
absent-absent)
2/0/26/149 6/7/17/684 <0.001 1/0/3/36 2/0/0/287 <0.001
Receiving treatment for HT, DL, and/or DM 
(yes/no)
59/118 181/533 0.032 10/30 39/250 0.055Predictive Factors for Fatty Liver
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and FBG in both sexes, and that alcohol intake did not have
any relation to the onset of fatty liver, in contrast with the
data from the Dionysos study [11]. Our present results were
partly in line with these findings, because 217 (13.8%) of
1578 participants developed fatty liver, which resolved in 74
(4.7%) participants, and the logistic regression analysis
revealed that alcohol consumption was not a predictor for
the development of fatty liver as previously reported [8, 12].
However, in contrast with the results by Kojima et al. [5],
not BMI but high percentage body fat in 2000 and increased
% change in percentage body fat during the follow-up period
in each participant were independent predictors for the
development of fatty liver in both sexes in the present study.
Eguchi et al. [13] reported that hepatic fat infiltration in
NAFLD might be influenced by visceral fat accumulation
regardless of BMI. Imamura et al. [14] also reported that
altered body composition, particularly increased percentage
body fat without an increase in BMI, was strongly associated
with the increasing prevalence of fatty liver.
Indeed, the change in BMI between 2000 and 2007–2008
was constantly associated with the development and regres-
sion of fatty liver in men regardless of the history of alcohol
intake in the present study. In contrast, in women, a high
percentage body fat in 2000 was associated with the
development of fatty liver in 2007–2008 regardless of
alcohol consumption. The BMI is chosen as a measure of
overall adiposity and elevated percentage body fat with
normal BMI can be presumed to reflect central body fat
distribution [8]. Lonardo et al. [12] reported that women
with fatty liver had a more central fat distribution, which
reflects visceral fat, than women without fatty liver, and
concluded that this central-type body fat distribution
predicted fatty liver only in women. Our results support
these data and sex differences in the pathogenesis and treat-
ment of fatty liver, particularly NAFLD, should be further
determined.
Metabolic syndrome-related disorders with abnormal
serum levels of T.Chol., TG, UA, and FBG were associated
with the development or regression of fatty liver in men and
women with or without alcohol intake in the present study.
Table 6. Comparison of clinical and laboratory features of fatty liver and non-fatty liver in 2007–2008 in participants who had fatty
liver in 2000 (n = 358)
Refer to the legends of Table 1 and 5 for abbreviations.
Feature
Men (n = 317) Women (n = 41)
Fatty liver 
in 2007–2008 
(n = 250)
Non-fatty liver 
in 2007–2008 
(n = 67)
p
Fatty liver 
in 2007–2008 
(n =3 4 )
Non-fatty liver 
in 2007–2008 
(n =7 )
p
Age (years) in 2000 47 (34–58) 47 (35–54) 0.889 47 (35–56) 46 (39–50) 0.282
Alcohol in 2000 (drinker/non-drinker) 158/92 50/17 0.080 1/33 3/4 0.012
Alcohol behavior 
(non-drinker/continuous/former drinker/others)
40/149/3/49 10/44/1/7 0.321 12/0/1/21 2/0/3/2 0.005
Physical exercise habit (yes/no) 66/182 16/51 0.689 2/32 2/5 0.128
BMI (kg/m2) in 2000 25.4 (19.1–45.1) 24.6 (19.1–29.8) 0.002 26.1 (21.5–41.3) 24.7 (21.1–27.6) 0.198
% change in BMI* +2.3 (−20.0–+18.7) −1.8 (−14.1–+9.6) <0.001 +3.0 (−10.4–+14.0) −0.1 (−9.1–+5.8) 0.125
% fat volume in 2000 25.8 (14.8–52.6) 24.2 (17.1–33.0) 0.012 35.8 (18.4–49.8) 31.6 (26.2–38.9) 0.144
% change in % fat volume* +1.5 (−41.4–+63.6) −4.7 (−32.5–+66.3) <0.001 +2.2 (−25.7–+84.8) +5.2 (−25.3–+9.3) 0.879
SBP (mmHg) in 2000 128 (79–171) 124 (79–161) 0.608 127 (98–162) 129 (105–153) 0.879
Change in SBP (mmHg)** −1 (−58–+43) −3 (−55–+24) 0.326 −4 (−50–+25) −7 (−39–+6) 0.672
DBP (mmHg) in 2000 80 (43–107) 80 (51–107) 0.691 79 (58–100) 77 (67–93) 0.906
Change in DBP (mmHg)** −4 (−38–+30) −5 (−32–+21) 0.900 −5.5 (−28–+13) −3 (−30–+2) 0.959
T.Chol. (mg/dL) in 2000 214 (140–320) 209 (142–317) 0.635 221 (136–271) 211 (178–248) 0.599
Change in T.Chol. (mg/dL)** ±0 (−107–+87) −7 (−79–+54) 0.241 +9 (−90–+73) +7 (−28–+76) 0.959
TG (mg/dL) in 2000 154 (36–586) 110 (48–753) 0.009 128 (49–336) 73 (40–132) 0.041
Change in TG (mg/dL)** ±0 (−378–+713) −6 (−545–+279) 0.400 +1.5 (−210–+193) ±0 (−6–+18) 0.826
UA (mg/dL) in 2000 6.4 (0.7–10.1) 6.0 (2.9–8.3) 0.017 4.9 (3.1–6.2) 4.2 (3.4–6.2) 0.799
Change in UA (mg/dL)** +0.2 (−5.8–+4.1) ±0 (−1.8–+1.8) 0.201 +0.4 (−1.2–+2.6) +0.5 (−0.2–+1.5) 0.826
FBG (mg/dL) in 2000 98.5 (76–243) 99 (80–197) 0.208 96.5 (77–128) 96 (88–111) 0.747
Change in FBG (mg/dL)** +8 (−125–+87) +3 (−32–+31) 0.001 +7 (−10–+63) −1 (−16–+4) 0.003
Tentative metabolic syndrome in 2000 
(present/absent)
53/197 11/56 0.387 2/32 0/7 1.000
Change in tentative metabolic syndrome between 
2000 and 2007–2008 
(present-present/present-absent/absent-present/
absent-absent)
43/10/47/150 5/6/3/53 0.001 2/0/7/25 0/0/0/7 0.305
Receiving treatment for HT, DL, and/or DM (yes/no) 102/148 23/44 0.336 14/20 2/5 0.534K. Omagari et al.
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However, the presence of “tentative metabolic syndrome”
was not an independent predictor for the development or
regression of fatty liver. Hamaguchi et al. [6] studied 4401
Japanese adults, and 308 (7.0%) of those participants
developed fatty liver, which resolved in 113 (2.6%) partici-
pants during the mean follow-up period of 414 days. In
their study population, the presence of metabolic syndrome
at baseline was one of the independent predictors for the
development and regression of fatty liver in both sexes. One
possible explanation for these discrepant results may be the
difference in diagnostic criteria of the metabolic syndromes.
In contrast with the ATP III criteria [15], which were
adopted by Hamaguchi et al. [6], the Japanese criteria for
the diagnosis of metabolic syndrome adopted in the present
study defined the presence of central obesity (waist
circumference) as a pre-requisite and indispensable factor
[10]. Because waist circumference was not available in our
study subjects, we followed the method used by Hamaguchi
et al. [6] and substituted a BMI ≥25 kg/m2 instead of waist
circumference. However, if the participants were not over-
weight as judged by BMI, they failed to be included in the
group of subjects with “tentative metabolic syndrome”. Since
International Diabetes Federation also proposed central
obesity (waist circumference) as an indispensable factor for
the diagnosis of metabolic syndrome [16], detailed evalua-
tion of metabolic syndrome including the measurement of
waist circumference should be performed in the near future.
Blood pressures, both SBP and DBP, and physical activity
were not independent predictors for the development or
regression of fatty liver in our study population. Donati et al.
[17] reported that insulin resistance, a factor independently
associated with fatty liver, was predicted by the presence of
arterial hypertension in non-obese, non-diabetic, non-heavy
alcohol drinking patients with arterial hypertensive and
normal liver enzymes. Akahoshi et al. [18] also reported that
non-obese male participants with fatty liver had the highest
odds ratio for hypertension. Unfortunately, we did not
perform such analysis, and the discrepancy between these
results and ours is unclear. The association between arterial
hypertension or physical activity and fatty liver remains
uncertain and requires further investigation. Physical activity
may also reduce the associated risk factors and prevent the
progression of fatty liver, especially NAFLD, but the
independent contribution on variations in liver fat is so far
Table 7. Comparison of clinical and laboratory features of fatty liver and non-fatty liver in 2007–2008 in participants who were
classified as non-drinkers and who did not have fatty liver in 2000 (n = 273)
Refer to the legends of Table 1 and 5 for abbreviations.
Feature
Men (n = 105) Women (n = 168)
Fatty liver 
in 2007–2008 
(n =1 9 )
Non-fatty liver 
in 2007–2008 
(n = 86)
p
Fatty liver 
in 2007–2008 
(n =2 2 )
Non-fatty liver 
in 2007–2008 
(n = 146)
p
Age (years) in 2000 49 (34–55) 48 (34–56) 0.809 47 (36–53) 46 (29–55) 0.409
Physical exercise habit (yes/no) 3/15 32/53 0.120 6/16 40/105 0.927
BMI (kg/m2) in 2000 23.2 (19.9–25.7) 21.4 (16.5–26.2) 0.003 22.5 (19.8–26.4) 21.4 (16.5–28.6) 0.001
% change in BMI* +4.3 (−1.9–+17.4) +1.0 (−8.4–+22.6) 0.006 +6.8 (−2.7–+19.6) ±0 (−17.7–+19.9) <0.001
% fat volume in 2000 20.9 (17.7–31.3) 18.7 (9.6–35.6) 0.006 30.4 (23.6–37.6) 25.9 (16.7–35.6) <0.001
% change in % fat volume* +8.5 (−6.4–+30.9) −0.5 (−29.7–+61.1) 0.016 +10.4 (−5.9–+38.0) −0.8 (−33.9–+106.0) <0.001
SBP (mmHg) in 2000 117 (100–140) 114 (83–149) 0.206 119.5 (85–158) 115 (79–163) 0.342
Change in SBP (mmHg)** +4 (−15–+23) +2 (−32–+32) 0.963 −1 (−42–+58) +2 (−38–+38) 0.457
DBP (mmHg) in 2000 73 (57–89) 72 (47–94) 0.405 72.5 (53–88) 71 (43–100) 0.544
Change in DBP (mmHg)** −3 (−19–+8) −1 (−17–+22) 0.191 −1.5 (−20–+16) −2 (−28–+20) 0.432
T.Chol. (mg/dL) in 2000 212 (183–255) 196.5 (133–328) 0.021 208 (162–307) 204.5 (106–309) 0.485
Change in T.Chol. (mg/dL)** +10 (−42–+33) +4 (−159–+77) 0.191 +26 (−67–+112) +19 (−44–+97) 0.231
TG (mg/dL) in 2000 116 (47–242) 81 (26–545) 0.001 67.5 (48–166) 63.5 (27–221) 0.210
Change in TG (mg/dL)** +13 (−54–+117) +10 (−382–+181) 0.606 +29.5 (−42–+167) +12.5 (−63–+192) 0.035
UA (mg/dL) in 2000 5.8 (2.8–8.7) 5.3 (2.1–7.8) 0.053 4.2 (2.0–6.6) 4.1 (2.3–7.5) 0.974
Change in UA (mg/dL)** +0.6 (−0.2–+1.6) +0.2 (−2.3–+2.8) 0.058 +1.1 (−0.6–+1.8) +0.4 (−1.1–+2.3) 0.004
FBG (mg/dL) in 2000 95 (79–102) 90 (78–108) 0.141 90 (78–132) 91 (65–120) 0.693
Change in FBG (mg/dL)** +6 (−5–+22) +4 (−14–+24) 0.431 +5.5 (−9–+42) +2 (−19–+76) 0.073
Tentative metabolic syndrome in 2000 
(present/absent)
0/19 0/86 — 1/21 0/146 0.131
Change in tentative metabolic syndrome between 
2000 and 2007–2008 
(present-present/present-absent/absent-present/
absent-absent)
0/0/2/17 0/0/1/85 0.084 1/0/0/21 0/0/0/146 0.131
Receiving treatment for HT, DL, and/or DM (yes/no) 2/17 17/69 0.515 6/16 23/123 0.183Predictive Factors for Fatty Liver
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unknown [19,  20]. In our study, there was a limitation
because self-reported information regarding habitual physical
activity, as well as alcohol consumption, can lead to under-
or over-reporting. A direct interview by trained medical staff
should have been performed to get accurate information
from individuals.
In conclusion, BMI and percentage body fat were strongly
associated with the development or regression of fatty liver
regardless of the history of alcohol intake in the present
study. Metabolic syndrome-related disorders such as serum
levels of T.Chol., TG, UA, and FBG were also associated
with such clinical features in some degree. Although most
patients with NAFLD have a benign clinical course [21], the
presence of multiple metabolic disorders can be associated
with potentially progressive and severe liver diseases
such as non-alcoholic steatohepatitis [22, 23]. Our present
data suggest that control of body weight in men and the
percentage body fat in women are particularly important for
the prevention or treatment of fatty liver, followed by the
control of dyslipidemia, hyperuricemia, and hyperglycemia.
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